Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

Short seller Scorpion Capital disclosed a short position in TransMedics Group Inc (NASDAQ:TMDX) accusing the organ transplant tech. company of fraudulent practices, including kickbacks, billing fraud, ...

EST TransMedics (TMDX) down 10% to $65.39 after Scorpion Capital short reportStay Ahead of the Market:Discover outperforming stocks and ...

Scorpion Capital said in a newly-issued short report that in “20 years of shorting, TransMedics (TMDX) is the most extreme and grotesque ...

NDAQ:TMDX) Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX ...

Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Bank of America sees no rate cuts in 2025 after December's strong jobs report, and Goldman Sachs whittles down its rate-cut ...

Transmedics replaced its CFO in early December. Management also narrowed fourth-quarter guidance to the lower half of the previous range. Can Transmedics reaccelerate growth after this slowdown ...

TransMedics Group, Inc. (NASDAQ:TMDX), a leading player in the organ transplant technology sector with a market capitalization of $2.55 billion, has been making waves in the medical device ...

TransMedics is a top dog and first mover in an important industry, but it sold off heavily after earnings. Despite the sell-off, the company has numerous growth drivers that make it compelling ...